Oyster Point Pharma Inc. said its nasal spray OC-O1 helped patients with dry eye disease achieve better tear production compared to vehicle, thereby meeting the main goal of mid-stage study.
The Princeton, N.J.-based biopharmaceutical company evaluated two doses of OC-O1 against a vehicle — a dermatologic drug product — in a phase 2 trial, dubbed Mystic to treat patients with dry eye disease, a condition where the tears are not able to provide adequate lubrication for the eyes.
Oyster Point, which went public in the latter half of 2019, said in a Jan. 12 press release that OC-O1 works by stimulating natural tear production in the eye.
The company said that following 84 days of treatment, both doses, the 1.2 milligram/milliliter dose and 0.6 milligram/milliliter dosage, of OC-O1 showed a statistically significant improvement on the Schirmer's test — used for determining whether the eye produces enough tears to keep it moist — compared to the vehicle.
OC-01 was well-tolerated for both the two doses and the number of people reporting any treatment-emergent adverse event was the same in the two groups of patients.
Oyster Point added that it expects to discuss data from a phase 3 trial, dubbed Onset-2, in dry eye disease by the middle of the year.